search
Back to results

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Primary Purpose

Breast Cancer

Status
Unknown status
Phase
Phase 2
Locations
Spain
Study Type
Interventional
Intervention
Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Sponsored by
Hospital Universitario Madrid Sanchinarro
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Older than 18 years
  • Pre or post menopause patient with histology confirmation of breast cancer status II or III, Her2+ confirmed by FISH technique.
  • Lesion bigger than 2cm.
  • life expectancy > 12 weeks.
  • Normal Heart function (LVEF>55%)
  • Patient should give his/her signed, written informed consent.

Exclusion Criteria:

  • Previous chemotherapy treatment.
  • Previous treatment with HER2 or VEGF inhibitors.
  • Pulmonary disease not controlled.
  • Hypertension not controlled (systolic > 150 mmHg and/or diastolic > 100 mmHg) or significant cardiovascular disease (CVA/cerebral hemorrhage (6 months before inclusion), myocardial infarction (6 months before inclusion), unstable angina, congestive cardiac disease ≥ NYHA 2, or serious cardiac arrhythmia requiring medication.
  • Antecedents of coagulopathy or clinically significant thrombosis.
  • Major surgery, open biopsy or significant trauma 28 days before the inclusion in the study or planned major surgery during the study.
  • Peripheral Neuropathy > CTC 2 at inclusion.
  • Altered renal function a. Creatinine > 2.0 mg/dL or 177 mmol/L. b.Proteinuria > 2+ with reactive stick(dipstick). If screening proteinuria 2+, collection of 24h urine must show a value of proteins of 1 g/24h.
  • Daily chronic treatment with corticosteroids
  • Daily chronic treatment with aspirin (> 325 mg/day) o clopidogrel (> 75 mg/day)
  • Antecedents or heritage evidence of bleeder diathesis or coagulopathy with risk of hemorrhage.
  • Antecedents of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months previous to the inclusion.
  • Active infection to be treated with iv antibiotics
  • Serious injury not curing, peptic ulcer or bone fracture.
  • Pregnant or active sexual patient not using contraceptive methods. or lactating woman
  • Current or recent treatment with another IMP or participation in another clinical trial (30 days before inclusion)
  • Another primary tumor (including primary brain tumors)within 5 years to the study inclusion, apart from in situ cervix carcinoma, skin squamous carcinoma, both if they are appropriately treated, or skin basal cell cancer if controlled.

Sites / Locations

  • Complejo Hospital Costa DelRecruiting
  • Hospital Ramón Y CajalRecruiting
  • Hospital UniversitarioRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet

Arm Description

Outcomes

Primary Outcome Measures

Pathologic response in breast and axilla

Secondary Outcome Measures

To evaluate tumor markers as potential predictors of the pathologic response

Full Information

First Posted
March 23, 2011
Last Updated
March 23, 2011
Sponsor
Hospital Universitario Madrid Sanchinarro
search

1. Study Identification

Unique Protocol Identification Number
NCT01321775
Brief Title
Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer
Official Title
Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
June 2010
Overall Recruitment Status
Unknown status
Study Start Date
August 2009 (undefined)
Primary Completion Date
February 2013 (Anticipated)
Study Completion Date
November 2013 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Hospital Universitario Madrid Sanchinarro

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the efficacy of the combined therapy Bevacizumab, trastuzumab and paclitaxel in neo-adjuvant therapy in patients with breast cancer HER 2+ followed by surgery and adjuvant therapy (Cyclophosphamide, Trastuzumab and Doxorubicin liposomal).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Intervention Description
Neo-adjuvant doses (12 weeks): Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week. Adjuvant doses: Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)
Primary Outcome Measure Information:
Title
Pathologic response in breast and axilla
Time Frame
16 weeks average
Secondary Outcome Measure Information:
Title
To evaluate tumor markers as potential predictors of the pathologic response
Time Frame
baseline and 16 weeks average

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Older than 18 years Pre or post menopause patient with histology confirmation of breast cancer status II or III, Her2+ confirmed by FISH technique. Lesion bigger than 2cm. life expectancy > 12 weeks. Normal Heart function (LVEF>55%) Patient should give his/her signed, written informed consent. Exclusion Criteria: Previous chemotherapy treatment. Previous treatment with HER2 or VEGF inhibitors. Pulmonary disease not controlled. Hypertension not controlled (systolic > 150 mmHg and/or diastolic > 100 mmHg) or significant cardiovascular disease (CVA/cerebral hemorrhage (6 months before inclusion), myocardial infarction (6 months before inclusion), unstable angina, congestive cardiac disease ≥ NYHA 2, or serious cardiac arrhythmia requiring medication. Antecedents of coagulopathy or clinically significant thrombosis. Major surgery, open biopsy or significant trauma 28 days before the inclusion in the study or planned major surgery during the study. Peripheral Neuropathy > CTC 2 at inclusion. Altered renal function a. Creatinine > 2.0 mg/dL or 177 mmol/L. b.Proteinuria > 2+ with reactive stick(dipstick). If screening proteinuria 2+, collection of 24h urine must show a value of proteins of 1 g/24h. Daily chronic treatment with corticosteroids Daily chronic treatment with aspirin (> 325 mg/day) o clopidogrel (> 75 mg/day) Antecedents or heritage evidence of bleeder diathesis or coagulopathy with risk of hemorrhage. Antecedents of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months previous to the inclusion. Active infection to be treated with iv antibiotics Serious injury not curing, peptic ulcer or bone fracture. Pregnant or active sexual patient not using contraceptive methods. or lactating woman Current or recent treatment with another IMP or participation in another clinical trial (30 days before inclusion) Another primary tumor (including primary brain tumors)within 5 years to the study inclusion, apart from in situ cervix carcinoma, skin squamous carcinoma, both if they are appropriately treated, or skin basal cell cancer if controlled.
Facility Information:
Facility Name
Complejo Hospital Costa Del
City
Marbella
State/Province
Malaga
ZIP/Postal Code
29600
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diego Perez, MD
Phone
0034951 97 66 69
Email
dipema2026@gmail.com
First Name & Middle Initial & Last Name & Degree
Diego Perez, MD
Facility Name
Hospital Ramón Y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Noelia Martinez, MD
Phone
003491 336 80 00
Email
mjnoelia@hotmail.com
First Name & Middle Initial & Last Name & Degree
Noelia Martinez, MD
Facility Name
Hospital Universitario
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Garcia, MD
Phone
003491 756 78 50
Email
lauraestevez@hospitaldemadrid.com
First Name & Middle Initial & Last Name & Degree
Laura Garcia, MD

12. IPD Sharing Statement

Learn more about this trial

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

We'll reach out to this number within 24 hrs